allulose as a glp 1 may increase GLP-1 - Macro Economic Trends and Risks Allulose as a GLP-1-Like Sugar:

The hallmark symptoms of gastroparesis that qualify for legal action encompass: Persistent nausea affecting up to 96% of gastroparesis patients, often worsening after meals Cyclic vomiting episodes lasting four weeks or longer, sometimes containing undigested food from meals eaten hours or days earlier Early satiety and inability to finish normal-sized meals due to feeling abnormally full Severe bloating and visible abdominal distension Upper abdominal pain and cramping, particularly after eating Unintentional weight loss and malnutrition from inability to maintain adequate nutrition Dehydration requiring emergency medical intervention or hospitalization Gastroesophageal reflux and heartburn from retained stomach contents The severity of gastroparesis symptoms often correlates poorly with the degree of delayed emptying measured by diagnostic tests, meaning patients can experience debilitating symptoms even with moderately delayed gastric emptying times

Specific vendor reviews provide additional context

The drug now carries a warning for severe pancreatitis and severe kidney injuries

Epitalon produces antioxidant effects in the body by activating antioxidant enzymes, such as glutathione peroxidase